Dr. Sablinski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
25
Short Hills, NJ 07078Phone+1 973-921-9115
Summary
- I am a board certified general surgeon, who left practice some 15 years ago to became a drug developer. I have over thirty years of experience in healthcare ranging from basic research through clinical practice to drug and biologics development, in a broad international setting of Europe, Japan, and US.
I believe that the current model of clinical development is fundamentally broken, and I became passionate about changing it by:
- converging modern information technology with drug development "know-how" to increase the speed and quality of advancement of pharmaceuticals and biologics pipelines
- exploiting an unlimited potential of "knowledge networking" to revolutionize drug development and therapeutic decisions
Currently I am a managing drug development at Celtic Therapeutics, and I recently co-founded Transparency Life Sciences, the first drug development company based on open innovation crowd sourcing and cyber medicine.
www.transparencyls.com
Education & Training
- Brigham and Women's HospitalPost-Doctoral Fellowship, 1988 - 1992
- Medical University of WarsawClass of 1981
Certifications & Licensure
- MA State Medical License 1996 - Present
Clinical Trials
- Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis Start of enrollment: 2010 Nov 01
- Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca Start of enrollment: 2016 Feb 01
Publications & Presentations
PubMed
- 74 citationsAcute Humoral Xenograft Rejection: Destruction of the Microvascular Capillary Endothelium in Pig-to-Nonhuman Primate Renal GraftsAkira Shimizu, Shane Meehan, Tomasz Kozlowski, T. Sablinski, Francesco L. Ierino
Laboratory Investigation; a Journal of Technical Methods and Pathology. 2000-06-01 - 42 citationsLong-term discordant xenogeneic (porcine-to-primate) bone marrow engraftment in a monkey treated with porcine-specific growth factors.T. Sablinski, David W. Emery, Rodney L. Monroy, Robert J. Hawley, Y. Xu
Transplantation. 1999-04-15 - 10 citationsDecreased graft-versus-host disease after haplotype mismatched bone marrow allografts in miniature swine following interleukin-2 treatmentTomasz Kozlowski, T. Sablinski, M. Basker, Hiroshi Kitamura, Thomas R. Spitzer
Bone Marrow Transplantation. 2000-01-01
Professional Memberships
- The Transplantation SocietyMember
Other Languages
- Polish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: